Skip to main content
Top
Published in: Medical Oncology 2/2012

01-06-2012 | Original Paper

Prognostic significance of galectin-3 and cyclin D1 expression in undifferentiated nasopharyngeal carcinoma

Authors: Mustafa Fuat Acikalin, Durmus Etiz, Melek Kezban Gurbuz, Erkan Ozudogru, Funda Canaz, Ertugrul Colak

Published in: Medical Oncology | Issue 2/2012

Login to get access

Abstract

Galectin-3 was shown to be involved in various biological events, including cell growth, adhesion, differentiation, angiogenesis, apoptosis, tumorigenesis, and metastasis. The prognostic significance of galectin-3 expression has already been evaluated in several cancers. However, its prognostic role has not been investigated in nasopharyngeal carcinoma. The loss of cell cycle control is one of the critical steps in the development of nasopharyngeal carcinoma. Cyclin D1 is one of the key proteins involved in cell cycle control and is essential for G1/S phase transition. Overexpression of cyclin D1 has been observed in several human cancers. In the present study, the expression of galectin-3 and cyclin D1 was evaluated with immunohistochemical analysis in 45 patients diagnosed as undifferentiated nasopharyngeal carcinoma and expression of these proteins was correlated with clinicopathological parameters and prognosis. Multivariate analysis showed that older age (>50 vs. ≤50) (P = 0.028), distant metastasis at presentation (M1 vs. M0) (P = 0.001), and increased galectin-3 expression (>5% vs. ≤5%) (P = 0.025) were independently correlated with poor overall survival. We found no statistically significant correlation between cyclin D1 immunoexpression and disease outcome. The Spearman’s correlation coefficient revealed a significant correlation between galectin-3 and cyclin D1 expression (r = 0.425; P = 0.004). Our findings suggested that the immunohistochemical analysis of galectin-3 might be useful in predicting prognosis in nasopharyngeal carcinoma.
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRef Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRef
2.
go back to reference Xu L, et al. Factors associated with overall survival in 1706 patients with nasopharyngeal carcinoma: significance of intensive neoadjuvant chemotherapy and radiation break. Radiother Oncol. 2010;96:94–9.PubMedCrossRef Xu L, et al. Factors associated with overall survival in 1706 patients with nasopharyngeal carcinoma: significance of intensive neoadjuvant chemotherapy and radiation break. Radiother Oncol. 2010;96:94–9.PubMedCrossRef
3.
go back to reference Liu MT, et al. Prognostic factors affecting the outcome of nasopharyngeal carcinoma. Jpn J Clin Oncol. 2003;33:501–8.PubMedCrossRef Liu MT, et al. Prognostic factors affecting the outcome of nasopharyngeal carcinoma. Jpn J Clin Oncol. 2003;33:501–8.PubMedCrossRef
4.
go back to reference Nakao K, Mochiki M, Nibu K, Sugasawa M, Uozaki H. Analysis of prognostic factors of nasopharyngeal carcinoma: impact of in situ hybridization for Epstein-Barr virus encoded small RNA 1. Otolaryngol Head Neck Surg. 2006;134:639–45.PubMedCrossRef Nakao K, Mochiki M, Nibu K, Sugasawa M, Uozaki H. Analysis of prognostic factors of nasopharyngeal carcinoma: impact of in situ hybridization for Epstein-Barr virus encoded small RNA 1. Otolaryngol Head Neck Surg. 2006;134:639–45.PubMedCrossRef
5.
go back to reference Nakamura T, et al. Chemoradiotherapy for locally recurrent nasopharyngeal carcinoma: treatment outcome and prognostic factors. Jpn J Clin Oncol. 2008;38:803–9.PubMedCrossRef Nakamura T, et al. Chemoradiotherapy for locally recurrent nasopharyngeal carcinoma: treatment outcome and prognostic factors. Jpn J Clin Oncol. 2008;38:803–9.PubMedCrossRef
6.
go back to reference Ho HC, et al. Prognostic influence of parapharyngeal extension in nasopharyngeal carcinoma. Acta Otolaryngol. 2008;128:790–8.PubMedCrossRef Ho HC, et al. Prognostic influence of parapharyngeal extension in nasopharyngeal carcinoma. Acta Otolaryngol. 2008;128:790–8.PubMedCrossRef
7.
go back to reference Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem. 1994;269:20807–10.PubMed Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem. 1994;269:20807–10.PubMed
8.
go back to reference Krześlak A, Lipińska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett. 2004;9:305–28.PubMed Krześlak A, Lipińska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett. 2004;9:305–28.PubMed
9.
go back to reference Nangia-Makker P, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol. 2000;156:899–909.PubMedCrossRef Nangia-Makker P, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol. 2000;156:899–909.PubMedCrossRef
10.
go back to reference Honjo Y, Nangia-Makker P, Inohara H, Raz A. Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res. 2001;7:661–8.PubMed Honjo Y, Nangia-Makker P, Inohara H, Raz A. Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res. 2001;7:661–8.PubMed
11.
go back to reference Raz A, et al. Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis. Int J Cancer. 1990;46:871–7.PubMedCrossRef Raz A, et al. Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis. Int J Cancer. 1990;46:871–7.PubMedCrossRef
12.
go back to reference Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 1997;57:5272–6.PubMed Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 1997;57:5272–6.PubMed
13.
go back to reference Sakaki M, et al. Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest. 2010;57:152–7.PubMedCrossRef Sakaki M, et al. Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest. 2010;57:152–7.PubMedCrossRef
14.
go back to reference Honjo Y, et al. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res. 2000;6:4635–40.PubMed Honjo Y, et al. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res. 2000;6:4635–40.PubMed
15.
go back to reference Xu XC, el-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol. 1995;147:815–22.PubMed Xu XC, el-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol. 1995;147:815–22.PubMed
16.
go back to reference Wang Y, et al. Regulation of prostate cancer progression by galectin-3. Am J Pathol. 2009;174:1515–23.PubMedCrossRef Wang Y, et al. Regulation of prostate cancer progression by galectin-3. Am J Pathol. 2009;174:1515–23.PubMedCrossRef
17.
go back to reference Castronovo V, et al. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol. 1996;179:43–8.PubMedCrossRef Castronovo V, et al. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol. 1996;179:43–8.PubMedCrossRef
18.
go back to reference van den Brule FA, et al. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol. 1996;27:1185–91.PubMedCrossRef van den Brule FA, et al. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol. 1996;27:1185–91.PubMedCrossRef
19.
go back to reference Piantelli M, et al. Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. J Clin Oncol. 2002;20:3850–6.PubMedCrossRef Piantelli M, et al. Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. J Clin Oncol. 2002;20:3850–6.PubMedCrossRef
20.
go back to reference Plzák J, et al. Galectin-3—an emerging prognostic indicator in advanced head and neck carcinoma. Eur J Cancer. 2004;40:2324–30.PubMedCrossRef Plzák J, et al. Galectin-3—an emerging prognostic indicator in advanced head and neck carcinoma. Eur J Cancer. 2004;40:2324–30.PubMedCrossRef
21.
go back to reference Wu CC, et al. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomic. 2005;5:3173–82.CrossRef Wu CC, et al. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomic. 2005;5:3173–82.CrossRef
22.
go back to reference Chou J, et al. Nasopharyngeal carcinoma–review of the molecular mechanisms of tumorigenesis. Head Neck. 2008;30:946–63.PubMedCrossRef Chou J, et al. Nasopharyngeal carcinoma–review of the molecular mechanisms of tumorigenesis. Head Neck. 2008;30:946–63.PubMedCrossRef
24.
go back to reference Michalides RJ, et al. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1997;123:497–502.PubMedCrossRef Michalides RJ, et al. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1997;123:497–502.PubMedCrossRef
25.
go back to reference Ayhan S, et al. The role of pRB, p16 and cyclin D1 in colonic carcinogenesis. Hepatogastroenterology. 2010;57:251–6.PubMed Ayhan S, et al. The role of pRB, p16 and cyclin D1 in colonic carcinogenesis. Hepatogastroenterology. 2010;57:251–6.PubMed
26.
go back to reference Al-Aynati MM, Radulovich N, Ho J, Tsao MS. Overexpression of G1-S cyclins and cyclin-dependent kinases during multistage human pancreatic duct cell carcinogenesis. Clin Cancer Res. 2004;10:6598–605.PubMedCrossRef Al-Aynati MM, Radulovich N, Ho J, Tsao MS. Overexpression of G1-S cyclins and cyclin-dependent kinases during multistage human pancreatic duct cell carcinogenesis. Clin Cancer Res. 2004;10:6598–605.PubMedCrossRef
27.
go back to reference Yurakh AO, et al. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol. 2006;50:506–15.PubMedCrossRef Yurakh AO, et al. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol. 2006;50:506–15.PubMedCrossRef
28.
go back to reference Michalides R, et al. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res. 1995;55:975–8.PubMed Michalides R, et al. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res. 1995;55:975–8.PubMed
29.
go back to reference Hwang CF, et al. Loss of cyclin D1 and p16 expression correlates with local recurrence in nasopharyngeal carcinoma following radiotherapy. Ann Oncol. 2002;13:1246–51.PubMedCrossRef Hwang CF, et al. Loss of cyclin D1 and p16 expression correlates with local recurrence in nasopharyngeal carcinoma following radiotherapy. Ann Oncol. 2002;13:1246–51.PubMedCrossRef
30.
go back to reference Lai JP, et al. Association between high initial tissue levels of cyclin d1 and recurrence of nasopharyngeal carcinoma. Laryngoscope. 2002;112:402–8.PubMedCrossRef Lai JP, et al. Association between high initial tissue levels of cyclin d1 and recurrence of nasopharyngeal carcinoma. Laryngoscope. 2002;112:402–8.PubMedCrossRef
31.
go back to reference Lin HS, Berry GJ, Sun Z, Fee WE Jr. Cyclin D1 and p16 expression in recurrent nasopharyngeal carcinoma. World J Surg Oncol. 2006;4:62.PubMedCrossRef Lin HS, Berry GJ, Sun Z, Fee WE Jr. Cyclin D1 and p16 expression in recurrent nasopharyngeal carcinoma. World J Surg Oncol. 2006;4:62.PubMedCrossRef
32.
go back to reference Fu ZJ, et al. Overexpression of CyclinD1 and underexpression of p16 correlate with lymph node metastases in laryngeal squamous cell carcinoma in Chinese patients. Clin Exp Metastasis. 2008;25:887–92.PubMedCrossRef Fu ZJ, et al. Overexpression of CyclinD1 and underexpression of p16 correlate with lymph node metastases in laryngeal squamous cell carcinoma in Chinese patients. Clin Exp Metastasis. 2008;25:887–92.PubMedCrossRef
33.
34.
go back to reference Weinberger PM, et al. Association of nuclear, cytoplasmic expression of galectin-3 with β-catenin/Wnt-pathway activation in thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2007;133:503–10.PubMedCrossRef Weinberger PM, et al. Association of nuclear, cytoplasmic expression of galectin-3 with β-catenin/Wnt-pathway activation in thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2007;133:503–10.PubMedCrossRef
35.
go back to reference Lin HM, Pestell RG, Raz A, Kim HRC. Galectin-3 enhances cyclin D1 promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene. 2002;21:8001–10.PubMedCrossRef Lin HM, Pestell RG, Raz A, Kim HRC. Galectin-3 enhances cyclin D1 promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene. 2002;21:8001–10.PubMedCrossRef
36.
go back to reference Ferrazzo KL, Neto MM, dos Santos E, dos Santos Pinto D, de Sousa SO. Differential expression of galectin-3, β-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary gland. J Oral Pathol Med. 2009;38:701–7.PubMedCrossRef Ferrazzo KL, Neto MM, dos Santos E, dos Santos Pinto D, de Sousa SO. Differential expression of galectin-3, β-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary gland. J Oral Pathol Med. 2009;38:701–7.PubMedCrossRef
Metadata
Title
Prognostic significance of galectin-3 and cyclin D1 expression in undifferentiated nasopharyngeal carcinoma
Authors
Mustafa Fuat Acikalin
Durmus Etiz
Melek Kezban Gurbuz
Erkan Ozudogru
Funda Canaz
Ertugrul Colak
Publication date
01-06-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9971-3

Other articles of this Issue 2/2012

Medical Oncology 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.